PACS.K
PACS.K maintains a debt-to-equity ratio of 0.53, indicating a moderate reliance on debt financing, and a current ratio of 1.07, suggesting limited short-term liquidity cushion. The company's return on equity of 20.23% is significantly higher than the typical industry benchmark, reflecting strong profitability relative to its equity base. However, its return on assets of 3.43% is below the median for its industry, indicating that the company is not efficiently utilizing its assets to generate returns. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification, which may expose it to regional economic or regulatory risks. The company's free cash flow of $141.7 million and operating cash flow of $404.2 million suggest a positive cash generation capability, but its capital expenditure of -$105.4 million indicates a reduction in investment in long-term assets. The risk assessment highlights a medium liquidity risk and a low dilution risk, with a key flag indicating that net cash is negative after subtracting total debt, which could affect the company's ability to meet short-term obligations. Recent filings and transcripts have not disclosed any major events that would significantly alter the company's financial or operational outlook.
Business. PACS.K operates in the healthcare facilities and services industry, providing biotechnology solutions and related services.
Classification. PACS.K is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a confidence level of 0.92.
- PACS.K has a strong return on equity but a weak return on assets, indicating efficient use of equity but poor asset utilization.
- The company's liquidity position is moderate, with a current ratio just above 1 and a negative net cash position after debt.
- Revenue concentration in a single segment and lack of geographic diversification pose potential risks.
- Analysts have a generally positive outlook, with a mean price target of $41.86 and no hold or sell recommendations.
- # RATIONALES
- {
- "margin_outlook_rationale": "The company's gross profit margin is expected to remain stable due to consistent cost management and pricing power.",
- "rd_outlook_rationale": "Research and development spending is projected to remain flat as the company focuses on optimizing existing product lines.",
- Net cash is negative after subtracting total debt.